stoxline Quote Chart Rank Option Currency Glossary
Abeona Therapeutics Inc. (ABEO)
4.4  -0.2 (-4.35%)    05-17 16:00
Open: 4.53
High: 4.62
Volume: 522,661
Pre. Close: 4.6
Low: 4.4
Market Cap: 181(M)
Technical analysis
2024-05-17 4:43:42 PM
Short term     
Mid term     
Targets 6-month :  7.46 1-year :  9.86
Resists First :  6.38 Second :  8.44
Pivot price 4.31
Supports First :  3.04 Second :  2.53
MAs MA(5) :  4.44 MA(20) :  4.25
MA(100) :  6.06 MA(250) :  4.85
MACD MACD :  -0.6 Signal :  -0.7
%K %D K(14,3) :  71 D(3) :  68.8
RSI RSI(14): 41.4
52-week High :  9.01 Low :  2.82
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ABEO ] has closed below upper band by 43.9%. Bollinger Bands are 46.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.63 - 4.65 4.65 - 4.67
Low: 4.33 - 4.37 4.37 - 4.39
Close: 4.35 - 4.41 4.41 - 4.44
Company Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Headline News

Thu, 16 May 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc ... - PR Newswire

Wed, 15 May 2024
Is Abeona Therapeutics (ABEO) Outperforming Other Medical Stocks This Year? - Yahoo Movies UK

Wed, 15 May 2024
Abeona Therapeutics: Q1 Earnings Snapshot | Region | - The Independent

Sun, 12 May 2024
Abeona Therapeutics Inc (NASDAQ:ABEO) Sees Significant Increase in Short Interest - MarketBeat

Sun, 12 May 2024
Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Up 62.6% in April - Defense World

Thu, 02 May 2024
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL (ABEO) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 41 (M)
Held by Insiders 2.26e+007 (%)
Held by Institutions 3.5 (%)
Shares Short 1,990 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.591e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 377.1 %
Return on Equity (ttm) -47 %
Qtrly Rev. Growth 3.5e+006 %
Gross Profit (p.s.) -63.3
Sales Per Share -164.94
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -37 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 12.41
Stock Dividends
Dividend 0
Forward Dividend 3.35e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android